Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Certified by Founder
Lodge
Kate Therapeutics
start up
United States
- San Diego, California
- 08/06/2023
- Series A
- $51,000,000
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.
- Industry Biotechnology Research
- Website https://www.katetherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kate-therapeutics/
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)